Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.